Immune checkpoint inhibitors (ICIs) that block inhibitory receptors, including programmed death 1 (PD-1), programmed death-ligand-1 (PD-L1), and cytotoxic T-lymphocyte antigen-4, are now available for cancer treatment as a single drug or in combination with other drugs (Robert, 2020). The gene discussed is PDCD1; the disease is cancer.